At Scripps Translational Science Institute (STSI) we use cutting edge genomic technologies in our effort to bridge the gap between discovery, translation, and treatment. By leveraging the remarkable progress being made in genomics, our studies seek to find underlying genetic causes for cancer, cardiovascular disease, rare disease, infectious diseases, and many other conditions. We focus on translational studies with immediate relevance to human health and with tremendous potential for innovation.
The goal of the MyGeneRank study is to determine how your genetic risk influences health decisions. The study utilizes a free mobile app that enables users with 23andMe data to calculate their genetic risk score for coronary heart disease (CAD).
Healthy Aging – Wellderly
The Wellderly study seeks to unlock the genetic secrets behind lifelong health, using whole-genome sequencing.
Researchers at STSI are using infectious disease genomics to investigate and track outbreaks caused by highly pathogenic viruses such as Ebola and Zika. They are also developing fast diagnostic platforms to test for multiple pathogens simultaneously.
Scientists at STSI are conducting a number of studies on Coronary Artery Disease (CAD) and Atrial fibrillation (AFib). Research includes the use of induced Pluripotent Stem Cells in combination with genome editing technologies to determine the impact of specific genetic variants linked to CAD, and determining genetic risk scores for AFib.
Essential Tremor & Parkinson’s Disease
The aim of the Genetic & Digital Diagnosis of Essential Tremor & Parkinson’s Disease (GAGDET-PD) trial is to determine whether essential tremor, a benign tremor disorder, and Parkinson’s Disease, a neurodegenerative disorder, can be differentiated via combined genetic testing and monitoring of tremors with a wristwatch-like accelerometer device.
That each of us is truly biologically unique is not fully appreciated. Now that it is possible to perform a comprehensive “omic” assessment of an individual, it has become abundantly clear that each of us has truly one-of-a-kind biological content.Eric Topol, MD